Polifarma

The Gastroenterology portfolio of Polifarma is growing

Polifarma entered into a new agreement with Mylan for selling and supplying both pharmaceutical products and food supplements to treat inflammatory liver diseases.

 

Rome, 3rd February 2020 – Polifarma announced an exclusive sales and distribution agreement – valid from January 2020 - with the global pharmaceutical company Mylan for both the pharmaceutical product Legalon and the food supplement Legalon E.

Thanks to this agreement and after many years of experience in the gastroenterology market, Polifarma was able to broaden its portfolio with an integrated offer (Legalon + Legalon E).

Legalon1 is a pharmaceutical product made of Silymarin and used to treat ethyl alcohol/psychiatric drugs/antiblastics/paracetamol poisoning.

Legalon E2 is a food supplement made of Silymarin, a mixture of bioflavonoids whose antioxidant action facilitates both the hepatic function and the removal of metabolic waste naturally produced by the body, and Vitamin E, which helps to protect cells from oxidative stress.

###

1 The pharmaceutical product Legalon includes the following formulations:

  • Legalon 70 mg coated tablets - 40 tablets
  • Legalon 140 mg coated tablets - 30 tablets
  • Legalon 200 mg effervescent granules - 30 sachets

2 The food supplement Legalon E includes the following formulation:

  • Legalon E 30 coated tablets.
Share

Sei un medico specialista?

Registrati al sito approfitta
dei contenuti e dei servizi a te dedicati!

Registrati Subito

 
 
Polifarma

Polifarma SpA - Share Capital €1,000,000.00 - fully paid up Comp. Register Rome - Tax Code 00403210586 - Economic Index (REA) Rome No. 11913 - VAT No. 00882341001